Matthijs van Haren

Dr. Matthijs van Haren

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Drug Discovery Today
Verified
Journal Article
Open access
YGYongzhi Gao
Yongzhi Gao
NMNathaniel I. Martin
Nathaniel I. Martin
MHMatthijs van Haren
Matthijs van Haren
Nicotinamide N-methyltransferase (NNMT) methylates nicotinamide (NA) to generate 1-methyl nicotinamide. Since its discovery 70 years ago, the appreciation of the role of NNMT in human health has evolved from serving only metabolic functions to also being a driving force in diseases, including a variety of cancers. Despite the increasing evidence indicating NNMT as a viable therapeutic target, the development of cell-active inhibitors against this enzyme is lacking. In this review, we provide an overview of the current status of NNMT inhibitor development, relevant in vitro and in vivo studies, and a discussion of the challenges faced in the development of NNMT inhibitors.

23 August 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
YGYongzhi Gao
Yongzhi Gao
MHMatthijs van Haren
Matthijs van Haren
NBNed Buijs
Ned Buijs
PIPaolo Innocenti
Paolo Innocenti
YZYurui Zhang
Yurui Zhang
NMNathaniel I. Martin
Nathaniel I. Martin
Nicotinamide N-methyltransferase (NNMT) methylates nicotinamide (vitamin B3) to generate 1-methylnicotinamide (MNA). NNMT overexpression has been linked to a variety of diseases, most prominently human cancers, indicating its potential as a therapeutic target. The development of small-molecule NNMT inhibitors has gained interest in recent years, with the most potent inhibitors sharing structural features based on elements of the nicotinamide substrate and the S-adenosyl-l-methionine (SAM) cofactor. We here report the development of new bisubstrate inhibitors that include electron-deficient aromatic groups to mimic the nicotinamide moiety. In addition, a trans-alkene linker was found to be optimal for connecting the substrate and cofactor mimics in these inhibitors. The most potent NNMT inhibitor identified exhibits an IC50 value of 3.7 nM, placing it among the most active NNMT inhibitors reported to date. Complementary analytical techniques, modeling studies, and cell-based assays provide insights into the binding mode, affinity, and selectivity of these inhibitors.

19 August 2021 in RSC Chemical Biology
Verified
Journal Article
Open access
PDF file
MHMatthijs van Haren
Matthijs van Haren
YZYurui Zhang
Yurui Zhang
VTVito Thijssen
Vito Thijssen
NBNed Buijs
Ned Buijs
YGYongzhi Gao
Yongzhi Gao
NMNathaniel I. Martin
Nathaniel I. Martin
Using an mRNA display screening technique, macrocyclic peptides were identified as potent, non-competitive inhibitors of nicotinamide N -methyltransferase.

23 October 2014 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
MHMatthijs van Haren
Matthijs van Haren
LULinda Quarles van Ufford
Linda Quarles van Ufford
EMEd E. Moret
Ed E. Moret
NMNathaniel I. Martin
Nathaniel I. Martin
The protein arginine N-methyltransferases (PRMTs) are a family of enzymes that function by specifically transferring a methyl group from the cofactor S-adenosyl-L-methionine (AdoMet) to the guanidine group of arginine residues in target proteins. The most notable is the PRMT-mediated methylation of arginine residues that are present in histone proteins which can lead to chromatin remodelling and influence gene transcription. A growing body of evidence now implicates dysregulated PRMT activity in a number of diseases including various forms of cancer. The development of PRMT inhibitors may therefore hold potential as a means of developing new therapeutics. We here report the synthesis and evaluation of a series of small molecule PRMT inhibitors designed to simultaneously occupy the binding sites of both the guanidino substrate and AdoMet cofactor. Potent inhibition and surprising selectivity were observed when testing these compounds against a panel of methyltransferases.

9 September 2016 in Biochemistry
Verified
Journal Article
Closed access
MHMatthijs van Haren
Matthijs van Haren
JTJavier Sastre Toraño
Javier Sastre Toraño
DSDavide Sartini
Davide Sartini
MEMonica Emanuelli
Monica Emanuelli
RPRichard Parsons
Richard Parsons
NMNathaniel I. Martin
Nathaniel I. Martin

24 July 2017 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
MHMatthijs van Haren
Matthijs van Haren
RTRebecca Taig
Rebecca Taig
JKJilles Kuppens
Jilles Kuppens
JTJavier Sastre Toraño
Javier Sastre Toraño
EMEd E. Moret
Ed E. Moret
NMNathaniel I. Martin
Nathaniel I. Martin
Nicotinamide N-methyltransferase (NNMT) is an enzyme that catalyses the methylation of nicotinamide to form N′-methylnicotinamide. Both NNMT and its methylated product have recently been linked to a variety of diseases, suggesting a role for the enzyme as a therapeutic target beyond its previously ascribed metabolic function in detoxification. We here describe the systematic development of NNMT inhibitors derived from the structures of the substrates involved in the methylation reaction. By covalently linking fragments of the NNMT substrates a diverse library of bisubstrate-like compounds was prepared. The ability of these compounds to inhibit NNMT was evaluated providing valuable insights into the structural tolerances of the enzyme active site. These studies led to the identification of new NNMT inhibitors that mimic the transition state of the methylation reaction and inhibit the enzyme with activity on par with established methyltransferase inhibitors.